Board of Directors

Jayne Shaw.jpeg

Jayne Shaw

Executive Chair

Trained as a Registered Nurse in the UK, on arrival in Australia she became a Director of Nursing and Chief Executive Officer of two private hospitals. Following this she established an Australian and International  consulting business which was sold to Healthsouth a large US Healthcare company. After  this she became the Co-founder of Vision Group an Opthalmic Doctor equity consolidation model which was successfully listed on the ASX.

Jayne joined a number of private Healthcare Boards involved with specialist consolidation including Cardiology, Orthopaedics, and Women’s Health she continued to work with Private Equity firms on local and International Healthcare transactions. Jayne, together with Ron Phillips was a co-owner of Sydney Breast Clinic and a co-founder of BCAL Diagnostics. Current Board positions are Critical Group – Heatley’s Industrial Supplies, The Woolcock Research Institute, and The Hareda Foundation established to invest in Women’s Health Initiatives.

Ron Phillips.jpg

The Hon Ron Philips (AO)

Biospecimen and Clinical Research

Following 15 years in the NSW Parliament which included serving as Minister for Health and Deputy Leader of the Opposition, Ron developed a successful consulting business in the Health and Aged Care Industry.

His business interests included co-owner and Managing Director of Sydney Breast Clinic which he sold to Healthscope. He currently serves as Chair of the Sydney Local Health District and as Director on Westmead IVF.


Jonathan Trollip

Independent Non-Executive Director

Jonathan is a globally experienced independent director with over 30 years commercial, corporate, governance and legal and transactional expertise. Jonathan is currently non-executive independent chairman of ASX listed Global Value Fund Ltd Future Generation Investment Company Ltd , Antipodes Global Investment Company Ltd and Plato Income Maximizer Limited . He is a non-executive director of ASX listed Kore Potash Limited and holds private company directorships in the commercial and not-for-profit sectors.

Jonathan was a principal of Sydney, Australia based structured finance group Meridian International Capital Limited for over 20 years, Prior to that, Jonathan was a partner with law firm Herbert Smith Freehills. Jonathan currently has a New South Wales Law Society Practicing Certificate and is a Fellow of the Australian Institute of Company Directors.


Merilyn Sleigh

Independent Non-Executive Director

Dr. Sleigh has over 30 years of experience as a senior executive and non-executive director in Australia’s biotechnology sector. She was, from its foundation, Chief Executive Officer and Managing Director of EvoGenix Limited, a biotech startup company that expanded internationally and listed on the ASX before acquisition by a larger company.

She was formerly Dean of the Faculty of Life Sciences, University of NSW; Director of Research & Development at Australian biotech Peptech Ltd and a research scientist and senior manager with CSIRO. She has held non-executive director positions with Mimetica Pty Ltd and Adalta Ltd as well as with ASX listed companies Clover Corporation, and Tyrian Diagnostics Ltd. 

Other director roles have been with government and not-for-profit organisations, including the Rural Industries Research and Development Corporation and Relationships Australia


Mark Burrows AO

Independent Non-Executive Director

Mark Burrows AO joined the BCAL Board on a pro-bono basis, as he is an advocate for early diagnosis of breast cancer and other cancers. He has enjoyed a long and distinguished career in investment banking both in Australia and the UK. Mark co-founded Baring Brothers Burrows & Co in Australia in the early 80s. In 1999 he was appointed the Managing Director/ Deputy Chairman of ING Barings in London. During his extensive investment banking career, Mark has been the principal financial advisor to some of the most significant and transformative corporate and government transactions in Australia. Mark has served as a non-executive director on several Australasian and UK public companies including Chairman and Deputy Chair of Brambles, Fairfax Media and Telstra.



Dr Amani Batarseh

Dr Amani Batarseh, PhD

Chief Scientific Officer

Dr Amani Batarseh is the company’s Chief Scientist. She graduated magna cum laude from La Roche College in Pennsylvania where she had a Pacem in Terris scholarship for academic excellence. Later, she received a fellowship to purse her PhD at Georgetown University, Washington, DC in Biochemistry and Molecular & Cellular Biology. Amani completed post doctoral studies at Harvard University, McGill University and Wollongong University. During her time in Canada, Amani managed and established two mass spectrometry laboratories being at the Research Institute of McGill University Hospital and The Glen Hospital in Montreal, respectively. Her versatile profile of expertise combines molecular biology with lipidomics and mass spectrometry to answer biological questions.

Kerry Heffernan.jpg

Kerry Heffernan

Research Assistant

Kerry is the company’s Research Assistant. Kerry recently graduated with First Class Honours from the University of Sydney. He presented his Honours project at the 2019 ASCEPT-PAGANs conference in Queenstown NZ.
Kerry as a diverse range of professional interests including health, carcinogenesis, machine learning, programming and metabolomics.


Charlie Lewis

Corporate Finance Advisor

Charlie has 30 years of global capital raising and mergers and acquisitions experience.  After a career holding senior positions at Baring Brothers, Macquarie Bank, Investec and EY, working in Australia, SE Asia, South Africa and the UK, he now runs an independent advisory boutique.  Charlie has an M&A in Economics from Cambridge University, is a Fellow of the Institute of Chartered Accountants in England and Wales and is a Graduate of the Australian Institute of Company Directors.


Mr Paul Cohen B.AppSc (Biomedical)

Clinical Trial Coordinator 

Paul has greater than 26 years’ experience in the diagnostics, biotechnology, medical device, and bio-pharmaceutical industry. His expertise spans clinical research, regulatory affairs, pharmacovigilance, training, quality management and process re-engineering for large pharmaceutical companies, biotech and medical device/IVD start-up ventures.

His clinical research therapeutic area expertise includes medical devices-CLASS I-III, IVDs, vaccines and biologicals, anti-infectives, transplantation, antidepressants, rheumatology, oncology, diabetes, respiratory and orthopaedics.

market/PV pre and post market obligations and risk management. He holds an ARCS Certified Fellowship in Clinical Research and is a member of ARCS, AIMS, ASM, RAPS and a Subject Matter Expert for the World Medical Device Organisation.


Rebecca Shaw

Marketing Manager

Experience across Consumer Healthcare, FMCG and Startups specialising in brand management and digital marketing. Rebecca has worked on some of Australia's market leading Consumer Healthcare brands such as Panadol, Voltaren, Centrum and Sensodyne to drive brand growth and sales.


Scientific Advisors 

kim ekroos.jpg

Dr Kim Ekroos, PhD

Lipidomics and Mass Spectrometry

Kim Ekroos is the founder and CEO of Lipidomics Consulting Ltd., a consulting business providing unique services for customers globally in the field of Lipidomics. He received his Ph.D. degree in biology from the Technical University in Dresden, Germany, in 2003. His expertise includes high-throughput technologies for the precise assessment of lipidomes enabled by advanced mass spectrometry, automation, and software tools towards discovery of biological architectures and of diagnostic biomarkers for clinical purpose.
Kim is a globally experienced independent consultant for Lipidomics with over 20 years academics, healthcare and industry expertise. He has a number of patents for biomarker discovery, numerous peer-reviewed publications and an editor of a widely read Lipidomics book. He is the current president of the newly founded International Lipidomics Society (ILS) to which the Lipidomics Standards.


A/Prof Craig Gedye
BSc(Hons), MBChB, FRACP, PhD

Biospecimen and Clinical Research

Craig Gedye is a medical oncologist and cancer researcher. He works for people with melanoma, brain, prostate, bladder and kidney cancers at the Calvary Mater Newcastle and is the Clinical Research Director at the NSW Health Statewide Biobank.
His research in the School of Medicine and Public Health at the University of Newcastle/Hunter Medical Research Institute focuses on complexity and heterogeneity in cancer – "why are cancers different between different people; why are cancers cells different to each other; what does this mean for each person’s treatment?"
Craig is leading several national cancer clinical trials for the ANZUP and COGNO trials groups, and is a member of the Mark Hughes Scientific Advisory Committee, HNEHLD Clinical Trials Ethics Subcommittee and ANZUP Cancer. He has been awarded numerous scholarships, fellowships, grants, investigator-initiated clinical trials, publications, conference presentations and prizes.